GFAP and Alzheimer disease: Meanwhile, neurodegenerative biomarkers like neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) were higher in COVID-19 patients than non-COVID-19 patients with mild cognitive impairment or Alzheimer’s disease (AD), and these markers were correlated with the severity of COVID-19 [4].